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INTRODUCTION
Progressive multifocal leukoencephalopathy (PML) is 
a rare, often fatal, opportunistic infection, associated with 
demyelinating process. PML is caused by John Cunningham 
(JC) polyomavirus, and predominantly affects patients with 
human immunodeficiency virus (HIV) infection or immuno-
compromised patients with impaired cell-mediated immunity, 
such as transplant recipients, patients on monoclonal anti-
body therapy, or patients with various oncologic and hemato-
logic disorders. These patients usually present with advanced 
immunosuppression at the time of diagnostic evaluation, 
and are commonly late for the treatment to be effective [1]. 
PML is associated with high morbidity and mortality. The 
classical neuroimaging pattern shows the presence of diffuse, 
often multifocal white matter lesion, involving subcortical 
U-fibers, typically without associated contrast enhancement, 
mass effect, and vasogenic edema [2,3]. The histopathological 
examination reveals the presence of demyelination, macro-
phage infiltration, bizarre astrocytes, and enlarged oligoden-
drocyte nuclei [4,5]. Although the definite diagnosis of this 
disease is obtained by brain biopsy, non-invasive biomarkers 
of PML are helpful to eliminate the need for the aforemen-
tioned invasive procedure, especially considering the fact that 
brain biopsy is non-diagnostic in 4-36% of patients with HIV 
infection [6,7]. The Neuroinfectious Disease Section of the 
American Association of Neurology, has recently established 
the criteria for the diagnosis of PML. According to these cri-
teria, the definitive diagnosis of PML requires the presence of 
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ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal, opportunistic infection, associated with demyelinating process. PML 
is caused by John Cunningham (JC) polyomavirus, and predominantly affects patients with human immunodeficiency virus (HIV) infection 
or other immunocompromised patients. The purpose of this study was to determine the role of magnetic resonance spectroscopy (MRS) in 
establishing the diagnosis of PML. MRS with long and short echo time was performed in two patients with PML associated with HIV infection 
and in one PML patient associated with chronic lymphocytic leukemia. The most prominent peak on the obtained spectra was for lactate; it 
showed 2-3 times higher concentration of lactate compared to choline, almost 4-6 times higher lactate concentration compared to creatine, and 
4-11 times higher lactate in comparison to N-acetylaspartate concentration. Similar spectrum pattern was observed in all patients. To the best of 
our knowledge, this is a new finding that might be useful in early diagnosis of PML. Nevertheless, further confirmation of our results is needed, 
since we analyzed the spectrum pattern only in three patients. Overall, our results could help in early detection of PML, especially in non-HIV 
patients, and thus prevent the fatal outcome of the disease. MRS could also be useful in detecting “tumefactive” demyelinating lesions in PML 
patients, associated with immune reconstitution inflammatory syndrome, to avoid misdiagnosis of neoplasm.
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demyelination confirmed by histology, bizarre astrocytes, and 
enlarged oligodendrocyte nuclei, coupled with the techniques 
for JC virus detection. However, the evidence of clinical and 
imaging manifestations consistent with the diagnosis, com-
bined with the presence of JC virus confirmed by polymerase 
chain reaction (PCR) of cerebrospinal fluid (CSF), and not 
explained by other disorders, is also considered diagnostic 
according to these new criteria [8]. The purpose of our study 
was to determine the role of magnetic resonance spectroscopy 
(MRS) in establishing the diagnosis of PML, since the early 
diagnosis could be crucial in preventing the fatal outcome. For 
instance, Pavlovic et al. [9] reported the regression of PML in a 
patient with lupus after early diagnosis and prompt discontin-
uation of immunosuppressive medications [9].
MATERIALS AND METHODS
MRS was performed in two HIV-positive patients and 
one patient with chronic lymphocytic leukemia, who had 
extensive brain lesions, involving the white matter on con-
ventional magnetic resonance imaging (MRI) examination. 
Clinical course and PCR of CSF were consistent with the 
diagnosis of PML. MR spectra were recorded on a 3T MRI 
scanner (Siemens Magnetom Trio, Erlangen, Germany), using 
single voxel MR spectroscopy with long and short echo time 
(TE), with  1H point resolved spectroscopy [PRESS] (svs_
se_135): Repetition time (TR) 2000 ms, TE 135 ms, voxel size 
20×20×20  mm, 128 averages, flip angle (FA) 90°, and acqui-
sition time 4:24  minutes, and STimulated Echo Acquisition 
Mode (STEAM)-20 (svs_se_20): TR: 2000 ms, TE: 20 ms, 
voxel size 20×20×20 mm, 176 averages, FA 90° and acquisition 
time 6:00 minutes. A voxel was placed inside the lesion. The 
peaks of N-acetylaspartate (NAA), choline (Cho), creatine 
(Cr), lactate (Lac), and lipids (Lip) were documented, and the 
ratios were expressed using creatine as reference.
RESULTS
Patient 1
A 36-year-old HIV+ male presented with fever, headache, 
and gradual left hemiparesis. Computed tomography (CT) of 
the thorax revealed the presence of pneumonia.
MRI revealed a large zone of low signal intensity on 
T1-weighted (T1W) images and high signal intensity on the 
T2W and fluid-attenuated inversion recovery (FLAIR) images, 
which included right parietal and frontal white matter, extend-
ing from the subcortical region to the right lateral ventricle, with 
involvement of the splenium of corpus callosum (Figure 1A-C). 
The lesion measured 6×5 cm in the axial plane. There was no 
contrast enhancement, gray matter involvement, or significant 
mass effect. MRS documented an increased Cho/Cr ratio 
(1.77), decreased NAA (NAA/Cr was 0.51), and extremely high 
Lac (Lac/Cr was 3.69) and Lip peaks (Lip/Cr was 3.15), which 
dominated in the obtained spectra both on the sequence with 
long (Figure 1D) and short TE (Figure 1E). Highly active antiret-
roviral therapy was administered but shortly after halted due 
to side effects, which were consistent with immune reconsti-
tution inflammatory syndrome [IRIS] (Figure 2A and B). The 
death occurred 3 months after the hospitalization.
Patient 2
A 40-year-old HIV+ male presented with 3-week-long 
fever, rash, vertigo, and right hemiplegia. MRI showed a large, 
low-signal-intensity lesion on the T1W image, predominantly 
located in the subcortical area, and a high-signal-intensity 
lesion on the T2W and FLAIR images, predominantly located 
in the subcortical areas of the left parietal and frontal lobes, 
with sharp demarcation toward gray matter (Figure  3A-C). 
The axial dimensions of the lesion were approximately 
6×4.5 cm. MRS documented an increased Cho/Cr ratio (2.29), 
decreased NAA (NAA/Cr was 0.82), and a high Lac peak 
(Lac/Cr was 2.30), which dominated in the obtained spec-
tra both on the sequence with long (Figure 3D) and short TE 
(Figure 3E). The death occurred 43 days after hospitalization.
Patient 3
A 77-year-old male with chronic lymphocytic leukemia, 
treated with chemotherapy and immunosuppressive medica-
tions (chlorambucil and pronison), presented with left hemi-
paresis, horizontal nystagmus, and left-sided tongue deviation. 
MRI revealed the presence of a large, subcortical lesion located 
in the right frontal and parietal lobes, T1W hypointense, T2W 
and FLAIR hyperintense, with a sharp border toward gray 
matter, measuring 10×3.5 cm in the axial plane (Figure 4A and 
B). MRS revealed an increased Cho/Cr ratio (1.84), decreased 
NAA (NAA/Cr ratio was 0.88), and an extremely high Lac 
peak (Lac/Cr ratio was up to 2.03), which dominated in the 
obtained spectra both on the sequence with long (Figure 4C) 
and short TE (Figure  4D). The death occurred 19  days after 
hospitalization.
DISCUSSION
The imaging characteristics of typical PML in patients who 
are HIV infected are well known [10]. An increasing number 
of patients on immunosuppressive therapy for autoimmune 
diseases are recognized in this context. Although the effective 
therapy has not been established yet, better management of 
patients may be achieved by withdrawal of immunosuppres-
sive drugs and reconstitution of the immune system, with pos-
sible better long-term survival [11,12]. The early recognition is 
351
Duško Kozić, et al.: MR spectroscopy in progressive multifocal leukoencephalopathy
especially important in non-HIV patients where, combined 
with appropriate therapy, it could lead to better healing. 
A recent report showed that PML was the first manifestation in 
a patient with a clinically occult sarcoidosis [13]. PML has also 
been described in an immunocompetent patient, in whom the 
administration of serotonin receptor targeted therapy improved 
the outcome [14]. This emphasizes the need for prompt diag-
nosis and monitoring of the disease process. Patients with 
autoimmune disorders should be particularly monitored for 
the development of PML during immunosuppressive therapy. 
Diffusion-weighted MRI (DW-MRI or DWI) can be used as 
an additional tool for monitoring the disease activity in patients 
with PML. Moreover, a report showed that DWI findings in 
PML patients are related to the disease stage [10]. Newer 
lesions and the advancing edges of large lesions showed nor-
mal-to-low apparent diffusion coefficient (ADC) values and a 
high signal on DWI, compared to older lesions and the centers 
of the large lesions that had increased ADCs and a low signal 
on DWI. These findings might also help to differentiate PML 
from mimicking diseases [10].
FIGURE 1. Magnetic resonance spectroscopy (MRS) signal characteristics of progressive multifocal leukoencephalopathy. (A) A large 
zone of low signal intensity on the axial T1-weighted (T1W) image and high signal intensity on (B) the coronal T2-weighted (T2W) and 
(C) axial fluid-attenuated inversion recovery images, in the right frontoparietal white matter. The involvement of the splenium of corpus 
callosum was also evident on the coronal T2W image. MRS with (D) long echo time [TE] and (E) short TE revealed increased choline, 
decreased N-acetylaspartate, and extremely high lactate and lipid peaks.
A
D E
B C
FIGURE 2. Rapid deterioration after treatment, associated with immune reconstitution inflammatory syndrome (IRIS), (A) mimicking 
the extension of high-grade glioma through the corpus callosum, on the axial T2-weighted (T2W) sequence. (B) An extremely high 
peak of lactate on magnetic resonance spectroscopy with long echo time (TE), that was more prominent compared to choline and 
N-acetylaspartate peaks, and consistent with non-neoplastic, tumefactive demyelinating lesions.
A B
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MRS is a non-invasive technique that evaluates the met-
abolic profile of the brain, by measuring the levels of several 
neurochemicals. The important peak, seen at 2.06  ppm in 
the proton spectrum of a healthy person, is related to NAA, 
a marker of neuronal integrity and function. A typical1H-MRS 
study of PML lesions shows a decrease of this metabolite. The 
increased Cho concentration, seen in patients with PML, 
highlights the presence of demyelination and increased cell 
membrane turnover. The elevated Lac peak observed in this 
disorder indicates increased macrophage activation after 
cell membrane breakdown, with consequent neuronal mito-
chondrial dysfunction and activation of anaerobic glycolysis. 
Since the level of Cr does not significantly change in the dis-
ease state, it is used as an internal standard. The myo-inositol 
(mI), a marker of glial inflammation, increases early in PML, 
but a decrease is seen in the later stages [15,16]. Several authors 
explained the typical MRS pattern of PML, which is associ-
ated with the increased Cho/Cr ratio, reduced NAA/Cr ratio, 
as well as the presence of Lac, Lip and mI peaks [10,17]. It was 
found that the acute lesions of PML survivors had a markedly 
increased mI to Cr ratio, compared to the lesions in patients 
whose disease progressed, suggesting that the inflammation 
limits the disease progression [18].
However, a number of other brain diseases, neoplastic 
as well as inflammatory, are characterized by the same neu-
rometabolic MRS pattern [17,19]. In addition, spectra with 
only Lac and/or Lip peaks have been evident in posttraumatic 
or neoplastic cavities [4,19]. Gheuens et al. [17] detected major 
differences in the metabolic profile of the brain lesions of PML 
patients with IRIS compared with the patients without IRIS. 
However, in their study, the Lac peak was not separated from 
the Lip peak due to the overlapping of these metabolites in 
the sequence with short TE, used for evaluation [17]. IRIS is 
defined as paradoxical worsening of a patient’s clinical condi-
tion associated with a recovery of the immune system after the 
initiation of combined antiretroviral therapy. The radiological 
finding may mimic high-grade glioma on conventional MRI, 
as shown in our patient (Figure 2A). However, MRS findings 
showing the presence of all metabolites, with Lac being the 
most prominent metabolite (Figure 2B), is not characteristic 
for glioblastoma or anaplastic astrocytoma. To the best of our 
knowledge, no other disorder has been documented in the lit-
erature, in which Lac is observed as the dominant metabolite 
(with higher concentration compared to Cho), in the spectra 
in which all metabolites are present. This finding was especially 
prominent in our study using 135 ms echo time in1H PRESS 
sequence, offering better signal-to-noise ratio and unequivo-
cal assignation of the Lac peak, due to its characteristic phase 
modulation. The increased Lac peak in patients with PML 
appears to be associated with the infiltration of macrophages 
and not caused by cellular hypoxia, since the “recovery” of 
Lac peak was revealed in the report of Pavlovic et al. [9], after 
the discontinuation of immunosuppressive medications in 
a patient with PML[9]. Cuvinciuc et  al. [20] reported serial 
FIGURE 3. (A) Axial T1-weighted [T1W], (B) T2W, and (C) fluid-attenuated inversion recovery (FLAIR) images showed a large T1W 
hypointense lesion, and a T2W and FLAIR hyperintense lesion in the left parietal and frontal lobes, consistent with progressive multifocal 
leukoencephalopathy. Magnetic resonance spectroscopy (MRS) with (D) long echo time [TE] and (E) short TE, showed an increased cho-
line, decreased N-acetylaspartate, and extremely high lactate peak.
A B
D E
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short TE  1H-MRS in a patient with PML-IRIS, where it was 
obvious that the Lac-Lip peak increased with time [20]. This 
may suggest that a Lac peak does not have to be increased at 
the onset of the disease. Future studies, with a larger cohort 
of PML patients, should confirm these observations and their 
diagnostic and prognostic value.
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